These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 9463283)

  • 1. [The molecular biology of bladder carcinoma].
    Moreno Sierra J; Maestro de las Casas ML; Chicharro Almarza J; Ortega Heredia MD; López García-Asenjo J; Merino Sánchez C; Blanco Jiménez E; Silmi Moyano A; Rsesel Estévez L
    Arch Esp Urol; 1997 Oct; 50(8):855-66. PubMed ID: 9463283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [New quantitative method for determining p53 protein in bladder carcinomas].
    Moreno Sierra J; Maestro de las Casas ML; Ortega Heredia MD; Chicharro Almarza J; Blanco Jiménez E; Silmi Moyano A; Resel Estévez L
    Arch Esp Urol; 1997 May; 50(4):347-53. PubMed ID: 9313043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bilharzial related, organ confined, muscle invasive bladder cancer: prognostic value of apoptosis markers, proliferation markers, p53, E-cadherin, epidermal growth factor receptor and c-erbB-2.
    Haitel A; Posch B; El-Baz M; Mokhtar AA; Susani M; Ghoneim MA; Marberger M
    J Urol; 2001 May; 165(5):1481-7. PubMed ID: 11342901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Usefulness of p53 oncoprotein immunohistochemistry in the follow-up of bladder carcinoma: a 5-year study].
    Moreno Sierra J; López García Asenjo JA; Redondo González E; Fernández Pérez C; Maestro de las Casas ML; Blanco Jiménez E; Silmi Moyano A; Resel Estévez L
    Arch Esp Urol; 1999 Oct; 52(8):840-8. PubMed ID: 10589115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Expression of PCNA/cyclin, p53, C-erbB-2 versus histological grade in transitional cell carcinoma of urinary bladder].
    Yoshikawa H; Ikeuchi T; Iguchi H; Onodera Y; Kai Y
    Hinyokika Kiyo; 1995 Apr; 41(4):253-8. PubMed ID: 7785554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of c-erbB-2 protein in normal and neoplastic urothelium: lack of adverse prognostic effect in human urinary bladder cancer.
    Lee SE; Chow NH; Chi YC; Tzai TS; Yang WH; Lin SN
    Anticancer Res; 1994; 14(3B):1317-24. PubMed ID: 7915094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sensitivity and specificity of p53 protein detection by immunohistochemistry in patients with urothelial bladder carcinoma.
    Salinas-Sánchez AS; Atienzar-Tobarra M; Lorenzo-Romero JG; Sánchez-Sánchez F; Giménez-Bachs JM; Donate-Moreno MJ; Pastor-Navarro H; Hernández-Millán I; Segura-Martín M; Escribano-Martínez J
    Urol Int; 2007; 79(4):321-7. PubMed ID: 18025850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic impact of p63 and p53 expression in upper urinary tract transitional cell carcinoma.
    Zigeuner R; Tsybrovskyy O; Ratschek M; Rehak P; Lipsky K; Langner C
    Urology; 2004 Jun; 63(6):1079-83. PubMed ID: 15183954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
    Stavropoulos NE; Filiadis I; Ioachim E; Hastazeris K; Tsimaris I; Kalogeras D; Stefanaki S; Agnantis NJ
    Anticancer Res; 2002; 22(6B):3759-64. PubMed ID: 12552989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of laminin-5 gamma2 chain and its prognostic significance in urothelial carcinoma of urinary bladder: association with expression of cyclooxygenase 2, epidermal growth factor receptor [corrected] and human epidermal growth factor receptor [corrected] 2.
    Kiyoshima K; Oda Y; Kinukawa N; Naito S; Tsuneyoshi M
    Hum Pathol; 2005 May; 36(5):522-30. PubMed ID: 15948119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p53 and p21 Expression levels predict organ preservation and survival in invasive bladder carcinoma treated with a combined-modality approach.
    Garcia del Muro X; Condom E; Vigués F; Castellsagué X; Figueras A; Muñoz J; Solá J; Soler T; Capellà G; Germà JR
    Cancer; 2004 May; 100(9):1859-67. PubMed ID: 15112266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular and immunohistochemical evaluation of epidermal growth factor receptor and c-erb-B-2 gene product in transitional cell carcinomas of the urinary bladder: a study in Greek patients.
    Gorgoulis VG; Barbatis C; Poulias I; Karameris AM
    Mod Pathol; 1995 Sep; 8(7):758-64. PubMed ID: 8539234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of bcl-2 and bcl-X in bladder cancer.
    Kirsh EJ; Baunoch DA; Stadler WM
    J Urol; 1998 Apr; 159(4):1348-53. PubMed ID: 9507882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transitional cell tumors of the ovary: a comparative clinicopathologic, immunohistochemical, and molecular genetic analysis of Brenner tumors and transitional cell carcinomas.
    Cuatrecasas M; Catasus L; Palacios J; Prat J
    Am J Surg Pathol; 2009 Apr; 33(4):556-67. PubMed ID: 19033864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Quantification of p53 oncoprotein in bladder carcinoma: 5-year experience].
    Moreno Sierra J; Maestro de las Casas ML; Fernández Pérez C; Redondo González E; Sanz Casla MT; del Barco Barriuso V; Blanco Jiménez E; Silmi Moyano A; Resel Estévez L
    Arch Esp Urol; 1999 Apr; 52(3):220-7. PubMed ID: 10371737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Expression of the tumor suppressor gene p53 in superficial transitional carcinoma of the bladder].
    Menéndez López V; Molina Porto R; Alcaráz Asensio A; Alvarez-Vijande García R; Alcover García JA; Ballesta Gimeno MA; Carretero González P
    Actas Urol Esp; 1998 Sep; 22(8):642-9. PubMed ID: 9835082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heparin-binding epidermal growth factor-like growth factor isoforms and epidermal growth factor receptor/ErbB1 expression in bladder cancer and their relation to clinical outcome.
    Kramer C; Klasmeyer K; Bojar H; Schulz WA; Ackermann R; Grimm MO
    Cancer; 2007 May; 109(10):2016-24. PubMed ID: 17394193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The relation between p53 overexpression and lymph node metastases in clinical stage t2 and t3a transitional cell bladder carcinoma.
    Uygur MC; Yaman I; Kutluay L; Altuğ U; Erol D
    J Exp Clin Cancer Res; 1999 Sep; 18(3):391-5. PubMed ID: 10606186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overexpression of HER-2/neu oncogene and transitional cell carcinoma of bladder.
    Jalali Nadoushan MR; Taheri T; Jouian N; Zaeri F
    Urol J; 2007; 4(3):151-4. PubMed ID: 17987577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decreased Fas expression in advanced-stage bladder cancer is not related to p53 status.
    Maas S; Warskulat U; Steinhoff C; Mueller W; Grimm MO; Schulz WA; Seifert HH
    Urology; 2004 Feb; 63(2):392-7. PubMed ID: 14972509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.